Quest Diagnostics (DGX) Tops Q3 EPS by 10c; updates guidance

Quest Diagnostics (NYSE: DGX) reported Q3 EPS of $2.60, $0.10 better than the analyst estimate of $2.50. Revenue for the quarter came in at $2.82 billion versus the consensus estimate of $2.73 billion.

GUIDANCE:

Quest Diagnostics sees FY2025 EPS of $9.76-$8.84, versus the consensus of $9.75. Quest Diagnostics sees FY2025 revenue of $10.96-11 billion, versus the consensus of $10.869 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Jefferies Downgrades Xior Student Housing NV (XIOR:BB) to Hold
• Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral